Search Results

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced plans to open a new office in London’s vibrant King’s Cross neighborhood.

Apollo Therapeutics, a biopharmaceutical company focused on translational biology and asset-centric drug development, and King’s College London, announced the formation of a new strategic collaboration.

Aclarion, Inc. announced their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK’s largest and most renowned independent hospitals.

Marengo Therapeutics, Inc. today announced a publication in Science Advances describing the novel immunological effects of its foundational anti-Vβ chain TCR targeting antibodies on human T cells.

NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to commence the largest trial of external Trigeminal Nerve Stimulation (eTNS) ever conducted.

In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King’s College London.

ENDRA Life Sciences Inc., a pioneer of enhanced ultrasound technologies, announced that King’s College Hospital, London is now partnering with ENDRA for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound device for assessing Non-Alcoholic Fatty Liver Disease.

EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London.